Premium
Humoral and cell‐mediated immunity to human papillomavirus type I (HPV‐ i ) in human warts
Author(s) -
KIENZLER J.L.,
LEMOINE M.TH.,
ORTH G.,
JIBARD N.,
BLANC D.,
LAURENT R.,
AGACHE P.
Publication year - 1983
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1983.tb01078.x
Subject(s) - antigen , papilloma , antibody , biology , virology , immune system , immunity , immunodiffusion , immunology , cellular immunity , humoral immunity , virus , capsid , medicine , pathology
SUMMARY The humoral and cell‐mediated immune response to human papillomavirus type i (HPV‐ i ) has been studied in 162 patients carrying papillomas of various clinical types: deep plantar wart or myrmecia, common wart, flat wart, and anogenital wart. Circulating antibodies were detected by immunodiffusion and microcomplement fixation, using purified HPV‐ i particles as type‐specific antigen. A significant association between myrmecia and anti‐HPV‐ i antibodies was found (39% of the cases). Cell‐mediated immunity was evaluated by a study of delayed hypersensitivity (DH). The main capsid components of HPV‐ i (HPV‐ i CP), consisting mostly of a polypeptide of molecular weight 54,000, were injected intradermally. In addition to the type‐specific antigens, HPV‐ i CP contain other antigenic determinants shared by various types of human papillomaviruses and masked in intact viral particles. The DH tests to HPV‐ i CP showed no differences between the carriers of different papilloma types, confirming the presence of common antigenic determinants. Moreover, they gave rise to an increase or to new anti‐HPV‐ i antibody production mostly in myrmecia carriers (78% and 33% of the cases, respectively), and to new DH to HPV‐ i CP in all groups of papilloma carriers (33% to 56%, depending on the clinical papilloma type).